We are an early-stage pharmaceutical company creating novel therapies for chronic pain, inflammation and headache disorders.
We are an early-stage pharmaceutical company creating novel therapies for chronic pain, inflammation and headache disorders.
Chronic pain is the #1 reason people seek healthcare. Our novel, non-addictive medicines and therapies aim to disrupt the $90 billion global market for pain pharmaceuticals.
- Assembled a team of worldwide experts in AI drug development, plant medicine, pain neurobiology and psychiatry, each with a career focused on reducing human suffering. Our team has more than 25 years of combined training under Clifford Woolf, MD, PhD, the Harvard Med School professor who first described how chronic pain is driven by central sensitization.
- Developed a transformative pharmaceutical development platform to address chronic pain by treating its physiological and psychological drivers.
- Began biological proof of concept experiments with our patented, first-in-class analgesic compounds.
